866-997-4948(US-Canada Toll Free)

Gamma Secretase (EC 3.4.23.)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 56 Pages

Gamma Secretase (EC 3.4.23.)-Pipeline Review, H2 2017

Summary

Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma Secretase (EC 3.4.23.)-Pipeline Review, H2 2017, outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Gamma Secretase (EC 3.4.23.)-Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 11 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Ear Nose Throat Disorders which include indications Alzheimer's Disease, Hearing Disorders, Acute Lymphoblastic Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Brain Cancer, Burkitt Lymphoma, Glioblastoma Multiforme (GBM), Leukemias, Medulloblastoma, Metastatic Breast Cancer, Soft Tissue Sarcoma, Solid Tumor and T-Cell Leukemia.

Furthermore, this report also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)
- The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Gamma Secretase (EC 3.4.23.)-Overview 7
Gamma Secretase (EC 3.4.23.)-Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 14
Gamma Secretase (EC 3.4.23.)-Therapeutics Assessment 16
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Gamma Secretase (EC 3.4.23.)-Companies Involved in Therapeutics Development 22
Astellas Pharma Inc 22
Bristol-Myers Squibb Co 22
Critical Outcome Technologies Inc 22
Lipopharma Therapeutics SL 23
Merck & Co Inc 23
NeuroGenetic Pharmaceuticals Inc 24
Pfizer Inc 24
Stemline Therapeutics Inc 25
Takeda Pharmaceutical Co Ltd 25
Gamma Secretase (EC 3.4.23.)-Drug Profiles 27
AS-2715348-Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
BMS-932481-Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
BMS-986133-Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
GSI-34-Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
LP-226A1-Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
LY-3056480-Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
NGP-328-Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
NGP-555-Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
nirogacestat-Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Peptides to Inhibit PSEN1 for Alzheimers Disease-Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
PF-06648671-Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SL-301-Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SL-302-Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease-Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease-Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Inhibit Beta and Gamma Secretase for Alzheimer's Disease-Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease-Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecules to Inhibit Gamma Secretase for Hearing Loss-Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecules to Inhibit PSEN1 for Alzheimer's Disease-Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Gamma Secretase (EC 3.4.23.)-Dormant Products 49
Gamma Secretase (EC 3.4.23.)-Discontinued Products 51
Gamma Secretase (EC 3.4.23.)-Product Development Milestones 52
Featured News & Press Releases 52
Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimers Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers 52
Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimers Disease; Reports Initial Results of Phase 1a Clinical Trial 52
Sep 29, 2014: FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimers Disease 52
Jun 16, 2014: Prof. G.L. Nicolson and Prof. R.M. Epand join Lipopharma's SAB 53
Jul 15, 2011: NeuroGenetic Pharma Receives SBIR Grant For Preclinical Development And IND Application Of NGP 555 To Treat Alzheimer's Disease 53
Jul 21, 2009: Critical Outcome Technologies Inc. Announces the Launch of a Drug Discovery Program for Alzheimers disease 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Number of Products under Investigation by Universities/Institutes, H2 2017 14
Products under Investigation by Universities/Institutes, H2 2017 15
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Stage and Route of Administration, H2 2017 19
Number of Products by Stage and Molecule Type, H2 2017 21
Pipeline by Astellas Pharma Inc, H2 2017 22
Pipeline by Bristol-Myers Squibb Co, H2 2017 22
Pipeline by Critical Outcome Technologies Inc, H2 2017 23
Pipeline by Lipopharma Therapeutics SL, H2 2017 23
Pipeline by Merck & Co Inc, H2 2017 24
Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2017 24
Pipeline by Pfizer Inc, H2 2017 25
Pipeline by Stemline Therapeutics Inc, H2 2017 25
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 26
Dormant Products, H2 2017 49
Dormant Products, H2 2017 (Contd..1), H2 2017 50
Discontinued Products, H2 2017 51

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Mechanism of Actions, H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 16
Number of Products by Routes of Administration, H2 2017 18
Number of Products by Stage and Routes of Administration, H2 2017 18
Number of Products by Molecule Types, H2 2017 20
Number of Products by Stage and Molecule Types, H2 2017 20

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *